Holen Sie sich die Stockscreener-App
7.57
0.13%
-0.010
Biocryst Pharmaceuticals Inc Aktie (BCRX) Neueste Nachrichten
Aug Highlights: Is BioCryst Pharmaceuticals Inc stock oversold or undervaluedJuly 2025 Sentiment & Risk Controlled Swing Alerts - moha.gov.vn
Alkeon Capital Management LLC Cuts Stock Holdings in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
FDA approves BioCryst’s oral pellet version of rare disease drug for children - WHTC
BioCryst wins FDA approval for Orladeyo oral pellets - MSN
FDA approves BioCryst's oral pellet version of swelling disorder drug for children - Reuters
BioCryst Pharma stock maintains Buy rating at TD Cowen on Orladeyo pediatric approval - Investing.com
Why are retail traders going gaga over BioCryst Pharma stock today? - MSN
BioCryst’s Orladeyo wins expanded FDA approval - The Pharma Letter
BioCryst Announces Board Chair Transition Plan - TipRanks
FDA approves berotralstat for patients aged 2 to 11 years with hereditary angioedema - Contemporary Pediatrics
Sector Update: Health Care Stocks Edge Higher Premarket Friday - marketscreener.com
Why Are Retail Traders Going Gaga Over BioCryst Pharma Stock Today? - Stocktwits
BioCryst stock rises after FDA approves ORLADEYO oral pellets for children - Investing.com Canada
FDA Approves BioCryst's (BCRX) Oral Pellet Formulation of Orlade - GuruFocus
BioCryst wins FDA nod for Orladeyo oral pellets (BCRX:NASDAQ) - Seeking Alpha
FDA Gives Green Light to BioCryst's (BCRX) ORLADEYO for Pediatri - GuruFocus
FDA approves BioCryst’s ORLADEYO oral pellets for HAE in children By Investing.com - Investing.com Australia
BioCryst Pharmaceuticals Announces FDA Approval of ORLADEYO Oral Pellets as First Targeted Prophylactic Therapy for Pediatric Patients with HAE Aged 2 and Older - Quiver Quantitative
FDA expands approval of BioCryst's rare disease drug for use in young children - marketscreener.com
BioCryst (Nasdaq: BCRX) gains FDA nod for 1st oral HAE prophylaxis, ages 2- - Stock Titan
Nebula Research & Development LLC Invests $2.57 Million in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
BioCryst Pharmaceuticals announces board chair transition following retirement notice By Investing.com - Investing.com Nigeria
BioCryst Pharmaceuticals announces board chair transition following retirement notice - Investing.com India
Hereditary Angioedema Clinical Trial Pipeline Expands as 20+ Companies Driving Innovation in the Therapeutics | DelveInsight - The Globe and Mail
Hood River Capital Management LLC Buys New Holdings in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Trading Action: Can BioCryst Pharmaceuticals Inc stock hit analyst price targetsJuly 2025 Catalysts & Trade Opportunity Analysis Reports - moha.gov.vn
BioCryst Pharmaceuticals, Inc. $BCRX Shares Bought by Jump Financial LLC - MarketBeat
JPMorgan Chase & Co. Grows Holdings in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
BioCryst Pharmaceuticals, Inc. $BCRX Shares Acquired by Russell Investments Group Ltd. - MarketBeat
Would You Still Hold BioCryst Pharmaceuticals Stock If It Fell 30%? - Trefis
BioCryst Pharmaceuticals, Inc. $BCRX Position Increased by Arrowstreet Capital Limited Partnership - MarketBeat
BioCryst Pharmaceuticals Inc. (BCRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Why BioCryst Pharmaceuticals Inc. stock is seen as undervalued2025 Short Interest & Verified Short-Term Trading Plans - Newser
Is BioCryst Pharmaceuticals Inc. stock a good choice for value investorsVolume Spike & Reliable Price Action Trade Plans - Newser
BioCryst Pharmaceuticals (NASDAQ:BCRX) Insider Alane Barnes Sells 19,770 Shares - MarketBeat
BioCryst Pharmaceuticals (NASDAQ:BCRX) Insider Sells $646,128.40 in Stock - MarketBeat
Insider Selling: BioCryst Pharmaceuticals (NASDAQ:BCRX) Insider Sells 50,906 Shares of Stock - MarketBeat
Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals - sharewise.com
BioCryst Pharma (BCRX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Panagora Asset Management Inc. Cuts Stock Holdings in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Biocryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
BioCryst (BCRX) Awards Stock Options and RSUs to New Employees - GuruFocus
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
How BioCryst Pharmaceuticals Inc. stock reacts to global recession fearsPortfolio Profit Report & Free Community Consensus Stock Picks - Newser
BioCryst receives antitrust clearance for Astria acquisition By Investing.com - Investing.com Canada
BioCryst’s Ongoing Boost: Buy or Watch? - StocksToTrade
BioCryst Pharmaceuticals Officer Sells Over 161K Shares - TradingView
Officer Barnes Files To Sell 19,770 Of BioCryst Pharmaceuticals Inc [BCRX] - TradingView
BioCryst Pharmaceuticals (BCRX): Valuation Check After Positive APeX-P Pediatric ORLADEYO Trial Update - Yahoo Finance
Biocryst receives early termination of Hart-Scott-Rodino waiting period for Astria acquisition - marketscreener.com
BioCryst Pharmaceuticals-Astria Deal Clears Regulatory Hurdle - marketscreener.com
BioCryst Pharmaceuticals Inc Announces Early HSR Termination for Astria Merger - TradingView
Astria Therapeutics (ATXS) Acquisition Moves Forward with Antitr - GuruFocus
BioCryst receives antitrust clearance for Astria acquisition - Investing.com India
BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition - The Manila Times
BioCryst Pharmaceuticals Announces Early Termination of HSR Waiting Period for Astria Therapeutics Acquisition - Quiver Quantitative
Prudential Financial Inc. Sells 159,975 Shares of BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Is BioCryst Pharmaceuticals Inc. stock resilient to inflation - Newser
Can BioCryst Pharmaceuticals Inc. stock sustain market leadershipJuly 2025 Action & Risk Managed Trade Strategies - Newser
Fisher Asset Management LLC Lowers Stake in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
1.48%
0.09%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):